A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune ...
On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu) vipivotide ...
MONTREAL, Feb. 3, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective February 1, 2025, Nova Scotia is publicly funding Pluvicto™ (lutetium (177Lu) ...
Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of PluvictoTM (INN: lutetium (177Lu) ...
Both are effective but work in slightly different ways: The newer of the two, lutetium-177, which was approved by the U.S. Food and Drug Administration (FDA) in 2022, can treat cancer that has ...
Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion. Pluvicto is ...
The U.S. FDA has approved Novartis AG’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan, formerly referred to as 177Lu-PSMA-617) for treating adults with metastatic prostate-specific membrane ...
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results